Co-Chairs, Nasser Altorki, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3xb6WS1. CME/MOC credit will be available until June 14, 2023.

1. Expanding Role and Use of Neoadjuvant and Adjuvant
Immunotherapy in Resectable Solid Tumors
Rationale and Current Approvals/Indications
Full abbreviations, accreditation, and disclosure information available at PeerView.com/GWF40
Neoadjuvant immunotherapy is administered before surgery and can reduce the
size of the primary tumor as well as eliminate residual cancers cells left after surgery
Rationale:
• Lower disease burden and intact
immune system
• T-cell response generated against
in situ primary tumor with diverse
antigen load
• Fast endpoints to assess response
• Allows for translational research:
biologic and immunologic
correlative studies
Rationale:
• Lower disease burden and intact
immune system
• Immunological pathways are
disrupted by surgical stress
• No risk for delaying surgery with
adjuvant versus neoadjuvant
approach
• Prior chemotherapy or other
systemic/local therapies may help
augment immune responses
Adjuvant immunotherapy is administered after surgery and leads to an increase
in activated T cells that can eliminate residual cancer cells in the tumor bed
Comparison of adjuvant and neoadjuvant immunotherapy treatment approaches1
Immunotherapy
T cells
T-cell activation Resection surgery
Solid tumor Resection surgery Immunotherapy T-cell activation
and additional
immunotherapy
Tumor cells Artery Healthy cells Immunotherapy

2. Expanding Role and Use of Neoadjuvant and Adjuvant
Immunotherapy in Resectable Solid Tumors
Rationale and Current Approvals/Indications
Full abbreviations, accreditation, and disclosure information available at PeerView.com/GWF40
 Overall survival (OS) is the gold-standard outcome measure for phase 3 trials, but the protracted length of these
clinical trials in resectable cancers makes this research daunting and expensive
 One strategy to expedite clinical trials, including those assessing immunotherapies in early-stage cancer settings,
is the use of newer, innovative surrogate measurements for endpoints
 Because pathologic response reflects a therapy’s ability to eradicate tumor cells more directly than radiographic
evaluation using RECIST criteria, it may better correlate with clinically meaningful outcomes
 Several trials in different tumor types have correlated the novel endpoints with more traditional endpoints such as OS,
DFS, and RFS, but additional confirmatory studies are needed
 Many adjuvant approvals have been based on disease-free survival (DFS)
 Trials in neoadjuvant settings provide an opportunity to assess pathologic response as an early surrogate marker
for survival outcomes, and pathologic response criteria such as major pathological response (MPR) and pathologic
complete response (pCR) have been assessed in neoadjuvant immunotherapy trials; there are various definitions,
but generally:
 MPR: ≤10% of viable tumor in the treated tumor bed
 pCR: complete absence of viable tumor in the treated tumor bed
 Recently, immune-related pathologic response criteria (irPRC) have also been developed with the aim of assessing
the full spectrum of response to immunotherapy in resection specimens
 Different scoring systems exist or are in development for evaluating pathologic response in various tumor types
(eg, melanoma, lung cancer, bladder cancer)
Relevant endpoints for neoadjuvant and adjuvant immunotherapy clinical trials2-8

3. Expanding Role and Use of Neoadjuvant and Adjuvant
Immunotherapy in Resectable Solid Tumors
Rationale and Current Approvals/Indications
Full abbreviations, accreditation, and disclosure information available at PeerView.com/GWF40
 Adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing
radical resection
 Adjuvant treatment of patients with completely resected esophageal or gastroesophageal junction cancer with
residual pathologic disease who have received neoadjuvant chemoradiotherapy
 Adjuvant treatment of patients with melanoma with lymph node involvement or metastatic disease who have
undergone complete resection
Current perioperative approvals and indications of immunotherapies in solid tumors9
Nivolumab
 Adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of
more than 1 mm who have undergone complete resection, including total lymphadenectomy
Ipilimumab
Newest Represents the first FDA approval for neoadjuvant therapy for early-stage NSCLC
 Neoadjuvant treatment of patients with resectable non–small cell lung cancer with platinum-doublet chemotherapy

4. Expanding Role and Use of Neoadjuvant and Adjuvant
Immunotherapy in Resectable Solid Tumors
Rationale and Current Approvals/Indications
Full abbreviations, accreditation, and disclosure information available at PeerView.com/GWF40
 Neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer with chemotherapy adjuvant treatment
after surgery as a single agent
 Adjuvant treatment of patients with renal cell carcinoma at intermediate-to-high or high risk of recurrence following
nephrectomy, or following nephrectomy and resection of metastatic lesions
 Adjuvant treatment of patients with stage IIB, IIC, or III melanoma following complete resection
 Patients with BCG-unresponsive, high-risk, non–muscle invasive bladder cancer with carcinoma in situ with or
without papillary tumors who are ineligible for or have elected not to undergo cystectomy
Current perioperative approvals and indications of immunotherapies in solid tumors9
Pembrolizumab
 Adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non–small
cell lung cancer whose tumors have PD-L1 expression on ≥1% of tumor cells
Atezolizumab
1. Krishnamoorthy M et al. J Natl Cancer Inst. 2021;113:823-832. 2. Topalian SL et al. Science 2020;367:eaax0182. 3. Benitez JC et al. Clin Cancer Res. 2020;26:5068-5077. 4. Bilusic M, Gulley JL. J Natl Cancer Inst. 2021;113:799-800. 5. Krishnamoorthy M et al. J Natl Cancer Inst. 2021;113:823-
832. 6. O’Donnell JS et al. Clin Cancer Res. 2019;25:5743-5751. 7. Hellmann MD et al. Lancet Oncol. 2014;15:e42-50. 8. Cottrell TR et al. Ann Oncol. 2018;29:1853-1860. 9. https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-
approval-notifications.

5. IASLC Multidisciplinary Recommendations
for Pathologic Assessment of Lung Cancer
Specimens Following Neoadjuvant Therapy1
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/GWF40
Recommendation 1
The term “tumor bed” is the area where the original pretreatment tumor was considered to be located. It can be
challenging to determine whether necrosis and stromal inflammation and/or fibrosis are due to regression secondary to
neoadjuvant therapy, native tumor characteristics, or a combination. For this reason we favor the term tumor bed. It is
suggested to simply describe the major components of the tumor bed as (1) viable tumor, (2) necrosis, or (3) stroma
(which can include inflammation or fibrosis). See page 3 for an example.
Recommendation 2
It is essential that information be provided from the surgical team to the pathology laboratory on whether the patient
received neoadjuvant therapy in order for this specimen processing protocol to be followed. If there is more than one
tumor in the specimen, it is of critical importance to also provide this information. It is good clinical practice to correctly
label the specimen with the lobe(s) resected and to clarify any issues that may be needed for pathologic staging such
as the pericardium, diaphragm, or chest wall.
Recommendation 3
Lung cancer resection specimens following neoadjuvant therapy should be sampled to optimize comprehensive gross
and histologic assessment of the lung tumor bed for pathologic response. The tumor should be cut in its greatest
dimension to maximize the tumor bed cross section. In cases where identification and/or orientation of the tumor are
difficult, review of the preoperative CT scan can be helpful. Tumors 3 cm or less in size should be completely sampled.
For larger tumors greater than 3 cm, the tumor should be cut across in serial sections 0.5 cm thick, and after gross
inspection, the most representative cross section showing viable tumor should be sampled. At least one cross section
of the entire tumor (0.5 cm thick) with a gross photograph and histologic mapping should be made. Histologic sections
at the tumor periphery should include 1 cm of adjacent lung parenchyma. Pathologic response cannot be assessed in
small biopsies; a resection specimen is required.
Recommendation 4
To determine the border of the tumor bed, the edge of the tumor needs to be distinguished from the surrounding
non-neoplastic lung parenchyma. This can be facilitated by review of the gross specimen and the histologic slides
from the periphery of the tumor bed.
Recommendation 5
Determination of the pathologic response to therapy should be made after review of all H&E slides of tumor by
estimating the percentages of (1) viable tumor, (2) necrosis, and (3) stroma, which includes both fibrosis and
inflammation, so each of these three components add up to 100%. Each component should be assessed in 10%
increments unless the amount is below 5% when an estimate of single percentages should be recorded. While this
is primarily done by review of histologic sections of the tumor bed, correlation with the gross findings, in some cases
facilitated by a gross photograph, may be important in markedly necrotic and/or cavitated tumors where it is not
possible to reflect this change in histologic sections.
Note: Although it may be useful to record the amount of each of these components on each individual histologic slide,
it needs to be kept in mind that the amount of tumor bed varies on each slide, so these percentages cannot be summed
and averaged as if they were in equal amounts. This is a semiquantitative process. There is no validated quantitative
method that is available that can be implemented in a timely fashion for clinical decisions.
A proposed synoptic template for reporting pathologic findings for resected lung cancers following neoadjuvant therapy
is summarized on page 2.

6. IASLC Multidisciplinary Recommendations
for Pathologic Assessment of Lung Cancer
Specimens Following Neoadjuvant Therapy1
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/GWF40
Recommended Synoptic Template for Recording Lung Cancers Following Neoadjuvant Therapy
Primary tumor
Type of neoadjuvant therapy
• No known presurgical therapy: _____
• Type of neoadjuvant therapy
– Chemotherapy: ____________________
– Radiotherapy: ____________________
– Immunotherapy (please specify): ____________________
– TKI (please specify): ____________________
– Other (please specify): ____________________
Treatment effect in primary tumor
• Percentage of viable tumor (record in 10% increments except below 10%; then record single digits between 1%-5%): _____
• No residual viable tumor identified: _____
• Percentage of necrosis: _____
• Percentage of stroma (includes fibrosis and inflammation): _____
Grade of inflammation (choose the appropriate grade)
_____ Mild
_____ Moderate
_____ Marked
Method (choose what was used for evaluation)
_____ Correlation was made with a gross photograph of tumor cut surface: Yes _____ No _____
_____ Evaluation was aided by use of tumor mapping to match a gross photograph to histologic sections: Yes _____ No _____
_____ Evaluation was aided by radiologic pathologic correlation: Yes _____ No _____
Treatment effect in lymph node metastases
• Total number of lymph node stations examined _____
• Total number of lymph nodes examined: _____
• No carcinoma present: _____
• Total number of lymph nodes with metastatic carcinoma: _____
• Lymph node stations involved by tumor with treatment-related changes: _____
• Lymph node stations with treatment-related changes without viable tumor: _____
• Largest tumor focus: mm at station number: _____
• Extracapsular extension present: _____
• No extracapsular extension: ____________________
Comments: ___________________________________________________________________________________________
_____________________________________________________________________________________________________

7. IASLC Multidisciplinary Recommendations
for Pathologic Assessment of Lung Cancer
Specimens Following Neoadjuvant Therapy1
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/GWF40
Histologic Components of the Tumor Bed
(A) Schematic image showing how percentage compositions are assigned. The tumor bed is divided into viable tumor area,
necrosis, and stroma. Stroma includes inflammation and fibrosis. (B) A representative hematoxylin-and-eosin stained slide image
(left) and a corresponding color illustration of the distribution of the components (right). The blue, red, and black areas represent
viable tumor, necrosis, and stroma, respectively.
Tumor bed = X + Y + Z = 100%
Viable tumor (X%)
Necrosis (Y%)
Stroma (Z%)
 Viable tumor = 50%
 Necrosis = 40%
 Stroma = 10%
A
B C
Tumor bed

8. IASLC Multidisciplinary Recommendations
for Pathologic Assessment of Lung Cancer
Specimens Following Neoadjuvant Therapy1
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/GWF40
Recommendation 6
Definition of major pathologic response (MPR)
MPR is defined as the reduction of viable tumor to the amount beneath an established clinically significant cutoff based
on prior evidence according to the individual histologic type of lung cancer and a specific therapy.
The historical definition of MPR for all histologic types of lung cancer is ≤ 10% of viable tumor with no viable tumor
required for pathologic complete response (pCR). MPR is calculated as the estimated size of viable tumor divided by
the size of the tumor bed. For the moment, this is the cutoff being used in multiple active clinical trials. However, recent
data suggests the MPR in the conventional chemotherapy setting may differ according to histologic type: ie,
adenocarcinoma versus squamous cell carcinoma.
If after review of histologic sections, the percentage of viable tumor is near the cutoff for major pathologic response,
additional histologic sections should be submitted. The pathology report should record the total number of blocks of
tumor bed that were examined even if the blocks did not consist entirely of tumor bed but also included some
uninvolved lung.
For colloid adenocarcinomas, where tumor cells are only focal, the mucin pools should be included in the percentage
of viable tumor. However, if there are only areas of extracellular mucin without any apparent viable tumor cells within
the mucin, we suggest regarding this as stroma. Further study is needed to address this point.
Major pathologic response can also be classified for the lung primary in the setting where the lung primary shows
little or no viable tumor, but lymph nodes show viable metastatic carcinoma (ypT0, N1, 2 or 3). However, the prognostic
and therapeutic implications of this clinical setting are not known.
Recommendation 7
Definition of pathologic complete response (pCR)
pCR is defined as lack of any viable tumor cells on review of H&E slides after complete evaluation of a resected lung
cancer specimen including all sampled regional lymph nodes. Such tumors would be staged as ypT0N0 according to
the 8th edition AJCC and UICC staging systems.
Note:
If no tumor is seen in the initial sections and tissue from the tumor bed remains, additional histologic sections should
be made. The number of additional sections should be whatever seems reasonable in the individual setting depending
on the size of the tumor bed and the capacity of the individual pathology laboratory. If the histologic changes in the initial
sections obtained do not show findings that fit for the effects of therapy, the possibility that the wrong area was sampled
should be considered. In such cases the gross specimen may need to be re-evaluated using radiologic pathologic
correlation and if additional lesions are identified, these should be sampled. The pathology report should record the
total number of blocks of tumor bed that were examined even if the entire block did not consist of tumor bed.
The identification of incidental lesions of squamous cell carcinoma in situ, atypical adenomatous hyperplasia,
adenocarcinoma in situ, or minimally invasive adenocarcinoma in the surrounding lung parenchyma that are clearly
separate from the main tumor for which neoadjuvant therapy was administered does not disqualify a case for
classification as MPR or CPR. This proposal is based on clinical judgement, as currently no clinical data exist to
make a specific recommendation.
In the setting of multiple tumors where a second invasive predominant lung carcinoma, is present that was regarded
preoperatively to be an intrapulmonary metastasis but, it is determined to be a second synchronous primary after
clinical, radiologic, pathologic, and/or molecular assessment, it is questionable whether the terms MPR or CPR should
be used if the main tumor otherwise meets the above criteria. No data exists currently to address this question.

9. IASLC Multidisciplinary Recommendations
for Pathologic Assessment of Lung Cancer
Specimens Following Neoadjuvant Therapy1
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/GWF40
1. Travis WD et al. J Thorac Oncol. 2020;15:709-740.
Recommendation 8
In the absence of more systemic data regarding evaluation of tumors following immunotherapy and molecular targeted
therapy, the same approach to pathologic assessment of resected lung cancers in the neoadjuvant setting in evaluating
the percentage of viable tumor, necrosis, and stroma should be used regardless of the type of neoadjuvant therapy
administered whether it was radiation, chemotherapy, targeted therapy, immunotherapy, chemoradiation,
chemoimmunotherapy, or chemotherapy-targeted therapy. There also may be different features that can be addressed
depending on the type of therapy such as immune cell infiltrates in patients who received immunotherapy.
Recommendation 9
In most cases, the lymph nodes are small enough to completely sample, but if there is a very large metastasis or tumor
bed (>2 cm), the lymph node can be bisected and the central slice through the tumor can be submitted in designated
cassettes. This should also be done during grossing of intraoperative frozen sections of lymph nodes. Depending on
individual laboratory resources, more extensive or even complete sampling can also be done. Then the same approach
can be used for histologic evaluation that is used for the resected lung cancer reporting percent viable tumor, necrosis,
and stroma. Complete pathologic response in a lymph node can be recognized if there is a well-defined scar and/or area
of tumor necrosis in the absence of identifiable viable tumor cells.
Recommendation 10
The following recommendations are made for T factor staging of neoadjuvant lung cancer resection specimens.
Tumor size:
If the viable tumor forms a discrete mass where the size can be measured with a ruler either grossly or microscopically
(where it can be measured on a single H&E slide), this is the preferred approach (Figure 2A-D). However, if the viable
tumor cannot be measured with a ruler either due to grossly indistinct borders, multiple foci interspersed among
necrosis and/or stroma, or if it is present on multiple slides, the viable invasive tumor size should be estimated using
the following formula.
Viable invasive tumor size (cm) = tumor bed size X percentage viable invasive tumor
Estimating invasive size by adjusting for lepidic component
In tumors that have a component of lepidic growth, tumor size estimation should use the principles introduced in the 8th
Edition TNM classification that record both total size and invasive size, but only use invasive size for T-factor
determination. Thus, in the neoadjuvant setting, viable tumor size estimation for such cases may need two adjustments:
one for invasive size excluding the lepidic component and a second for the percent viable tumor as outlined above.
However, the clinical implications of this adjustment for the lepidic component are not known in the neoadjuvant setting.
T3: multiple tumors considered to represent intrapulmonary metastases
If there is more than one tumor within a lobe, the pathological response or percent viable tumor should be reported for
each tumor unless the number of intrapulmonary metastases are too numerous to count.
Recommendation 11
Ongoing neoadjuvant studies with targeted therapies and immunotherapies in resectable NSCLC represent a unique
source of information, and the International Association for the Study of Lung Cancer strongly recommends and will
promote the design and implementation of an international database to collect uniformly clinical and pathologic
information with the ultimate goal of fostering collaboration and to facilitate the identification of surrogate end points
of long-term survival.

10. Immune-Related Adverse Events of
Cancer Immunotherapies
Become Aware and Stay Vigilant1-4
Full abbreviations, accreditation, and disclosure information available at PeerView.com/GWF40
What Are irAEs?
• Immune checkpoint inhibitors are associated with important clinical benefits, but general immunologic enhancement
can also lead to a unique spectrum of immune-related adverse events
• Any organ system can be affected, but more commonly occurring are pulmonary (pneumonitis), dermatologic (rash, pruritus,
blisters, ulcers, vitiligo), gastrointestinal (diarrhea, enterocolitis, transaminitis, hepatitis, pancreatitis), and endocrine
(thyroiditis, hypophysitis, adrenal insufficiency) irAEs
Endocrine
Hyper- or hypothyroidism
Hypophysitis
Adrenal insufficiency
Diabetes
Hepatic
Hepatitis
Renal
Nephritis
Dermatologic
Rash
Pruritus
Psoriasis
Vitiligo
DRESS
Stevens-Johnson
Hematologic
Hemolytic anemia
Thrombocytopenia
Neutropenia
Hemophilia
Ocular
Uveitis
Conjunctivitis
Scleritis, episcleritis
Blepharitis
Retinitis
Respiratory
Pneumonitis
Pleuritis
Sarcoid-like granulomatosis
Cardiovascular
Myocarditis
Pericarditis
Vasculitis
Gastrointestinal
Colitis
Ileitis
Pancreatitis
Gastritis
Neurologic
Neuropathy
Guillain Barŕe
Myelopathy
Encephalitis
Myasthenia
Musculoskeletal
Arthritis
Dermatomyositis
Prevention Anticipation
Treatment
Monitoring Detection

11. Immune-Related Adverse Events of
Cancer Immunotherapies
Become Aware and Stay Vigilant1-4
Full abbreviations, accreditation, and disclosure information available at PeerView.com/GWF40
Guidance for Surgeons: Suspect, Detect, and Refer for Treatment5,6
• irAEs frequently occur in the perioperative setting, either before or after surgical intervention
• irAEs occurring during neoadjuvant immunotherapy are generally manageable and in most cases should not exclude
patients from surgery
• The onus is on the surgeon to have a high degree of suspicion for potential toxicities in patients treated with immunotherapy
• Vague symptoms should not be dismissed, because nonspecific ailments can be indicative of severe toxicity
– Rheumatologic toxicities and endocrinopathies are some of the most difficult to recognize, given their relatively
nonspecific presentation
» For example, fatigue, poor energy, and low mood could represent hypophysitis or adrenal insufficiency
– Other toxicities can be essentially asymptomatic
» For example, renal and hepatic toxicity are generally only detected on routine labs
– Pneumonitis is another relevant irAE requiring awareness by surgeons, as severe pneumonitis could potentially
exclude patients from operative therapy, but significant pneumonitis has been rare in trials to date
• A comprehensive workup for irAEs, with a thorough history specifically targeted to potential irAEs, should be conducted
• Coordinate and collaborate with oncologists and other multidisciplinary experts to optimally diagnose and manage irAEs
in patients who have received/are receiving perioperative immunotherapy
• The National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) have issued
guidelines for recognition and management of immune-related adverse events

12. Immune-Related Adverse Events of
Cancer Immunotherapies
Become Aware and Stay Vigilant1-4
Full abbreviations, accreditation, and disclosure information available at PeerView.com/GWF40
How Should irAEs Be Diagnosed and Managed?
Minimal or No Symptoms; Diagnostic Changes Only
• In general, immunotherapy should be continued with close monitoring, with the exception of some neurologic, hematologic, and
cardiac toxicities
Mild to Moderate Symptoms
• Hold checkpoint inhibitor therapy for most grade 2 toxicities
• Consider resuming immunotherapy when symptoms and/or lab values revert to grade 1
• Corticosteroids (initial dose of 0.5-1.0 mg/kg/day of prednisone or equivalent) may be administered
Severe or Life-Threatening Symptoms
Grade 3 toxicities
• Hold checkpoint inhibitor therapy
• Initiate high-dose corticosteroids (prednisone 1-2 mg/kg/day or methylprednisolone IV 1-2 mg/kg/day)
• If symptoms do not improve with 48-72 hours of high-dose corticosteroid, infliximab may be offered for some toxicities
• Taper corticosteroids over the course of at least 4-6 weeks
• When symptoms and/or laboratory values revert to grade 1, rechallenging with immunotherapy may be considered; however,
caution is advised, especially in those patients with early-onset irAEs; dose adjustments are not recommended
Grade 4 toxicities
• In general, permanent discontinuation of checkpoint inhibitor therapy is warranted, with the exception of endocrinopathies that have
been controlled by hormone replacement
irAEs are often
diagnosed by exclusion;
other causes should be
ruled out (including AEs
of other therapies used),
but immunotherapy-related
toxicity should always be
included in the differential
There should be a high
level of suspicion that
new symptoms are
treatment related; early
recognition, evaluation,
and treatment of irAEs
plus patient education
are essential for the
best outcome
Depending on severity
of irAE, management
may require
corticosteroid or other
immunosuppressive
treatment and
interruption or
discontinuation of therapy
If appropriate
immunosuppressive
treatment is
used, patients generally
recover from irAEs
Use of immunosuppressive
therapy to manage
irAEs does not appear to
impact response to
immunotherapy
Grade 1
Grade 2
Grade 3/4

13. Immune-Related Adverse Events of
Cancer Immunotherapies
Become Aware and Stay Vigilant1-4
Full abbreviations, accreditation, and disclosure information available at PeerView.com/GWF40
 Hold immunotherapy with radiographic evidence of pneumonitis progression
 May offer one repeat CT in 3-4 weeks; in patients who have had baseline testing, may offer a repeat
spirometry/DLCO in 3-4 weeks
 May resume immunotherapy with radiographic evidence of improvement or resolution; if no improvement,
should treat as grade 2
 Monitor patients weekly with history, physical examination, and pulse oximetry; may also offer CXR
Grade 2: Symptomatic; >1 lobe
of lung or 25%-50% of lung
parenchyma; medical intervention
indicated; limiting instrumental ADL
Grade 3: Severe symptoms
requiring hospitalization; involves
all lung lobes or >50% of lung
parenchyma; limiting self care
Grade 4: Life-threatening
respiratory compromise; urgent
intervention indicated (intubation)
 Hold immunotherapy until resolution to grade ≤1
 Prednisone 1-2 mg/kg/day and taper by 5-10 mg/week over 4-6 weeks
 Consider bronchoscopy with BAL
 Consider empiric antibiotics
 Monitor patients every 3 days with history, physical examination, and pulse oximetry; consider CXR; if no clinical
improvement after 48-72 hours of prednisone, treat as grade 3
 Discontinue immunotherapy
 Empiric antibiotics; methylprednisolone IV 1-2 mg/kg/day; if no improvement after 48 hours, may add infliximab
5 mg/kg, or mycophenolate mofetil IV 1 g 2x/day, or IVIG x 5 days, or cyclophosphamide
 Taper corticosteroids over 4-6 weeks
 Pulmonary and infectious disease consults if necessary
 Bronchoscopy with BAL +/- transbronchial biopsy
 Patients should be hospitalized for further management
How Should Pulmonary irAEs Be Diagnosed and Managed?
 Pneumonitis: focal or diffuse inflammation of the lung parenchyma (typically identified on CT imaging)
 Diagnostic work-up: CXR, CT, pulse oximetry; for grade ≥2, may include infectious work-up
Grade 1: Asymptomatic; confined
to 1 lobe of lung or <25% of lung
parenchyma; clinical or diagnostic
observations only
Additional considerations
• GI and pneumocystis prophylaxis may be offered to patients on prolonged steroid use (>12 weeks)
• Consider calcium and vitamin D supplementation with prolonged steroid use
• Bronchoscopy + biopsy; if clinical picture is consistent with pneumonitis, no need for biopsy
1. Brahmer JR et al. J Clin Oncol. 2018;36:1714-1786. 2. Postow MA et al. N Engl J Med. 2018;378:158-168. 3. Gordon R et al. Clin J Oncol Nurs. 2017;21(suppl 2):45-52. 4. Champiat S et al. Ann Oncol. 2016;27:559-574. 5. Helmink BA et al. Ann Surg Oncol. 2020;27:1533-1545.
6. Stiles BM et al. J Thorac Cardiovasc Surg. 2020;160:1376-1382.

14. Simple Summaries of Significant Studies
CheckMate -816 Study of Nivolumab Plus Chemotherapy Before Surgery for NSCLC1
Full abbreviations, accreditation, and disclosure information available at PeerView.com/GWF40
358 people from 14 different countries
The researchers
created 2 groups
Who took part in this study?
What treatments were used?
Why is this study important?
Some people with non–small cell lung cancer (NSCLC)
have tumors that can be removed surgically. However,
the cancer often comes back or spreads to other parts
of the body, which may subsequently lead to death
Taking chemotherapy (chemo) before or after surgery
can reduce the risk of cancer coming back and may
help people live longer. However, this only works for
some people
Nivolumab (nivo) is an immunotherapy; it works by
activating a person’s immune system to fight back
against cancer cells
The goal of the CheckMate -816 study was to find out if
nivo plus chemo works better than chemo alone when
given before surgery for NSCLC
179 people in the
nivo plus chemo
group
179 people in
the chemo
alone group
Average age
64 years
All had tumors (4 centimeters or larger) in the lungs (and in some
cases, the nearby lymph nodes) that could be removed with surgery
IIIA
IIB
IIA
IB
As the number and letter goes
up, this represents a bigger
tumor and/or more spread
Staging is part of the lung cancer diagnosis.
This study included people with stages IB,
IIA, IIB, and IIIA NSCLC
7 in 10 were men 6 in 10 had stage IIIA NSCLC
Each treatment was taken
once every 3 weeks for a
total of 3 times
Surgery planned to
happen within 6 weeks
of the last dose

15. Simple Summaries of Significant Studies
CheckMate -816 Study of Nivolumab Plus Chemotherapy Before Surgery for NSCLC1
Full abbreviations, accreditation, and disclosure information available at PeerView.com/GWF40
What did the researchers look at?
What were the main results?
Nivo plus
chemo
Nivo plus
chemo
Nivo plus
chemo
Median EFS (number of months
half of the people lived without the
cancer getting worse or spreading)
People who took nivo plus chemo and had a pCR after surgery
lived longer without the cancer getting worse or spreading than
those who did not have a pCR
People alive at 2 years without
the cancer getting worse or
spreading
Chemo
Chemo
Chemo
8 in 10 7-8 in 10
0-1 in 10
2-3 in 10
4-5 in 10
Event-free survival (EFS)
How long did each person
live without the cancer
getting worse or spreading?
PRIMARY
ASSESSMENTS
ADDITIONAL
ASSESSMENTS
Pathological complete response (pCR)
Were there any cancer cells remaining in
the tissue samples obtained from the
lungs and lymph nodes after surgery?
Overall survival
How long did each person
live after starting
treatment?
What adverse events
did people have?
Most people went on to have surgery in both the nivo plus
chemo and chemo groups
People who took nivo plus chemo lived longer without the
cancer getting worse or spreading (EFS)
There was a trend for people who took nivo plus chemo to live
longer overall than those who took chemo alone. This remains to
be confirmed over time in the study
More people who took nivo plus chemo than who took chemo
alone had no remaining cancer cells in tissue samples obtained
from the lungs and lymph nodes after surgery (pCR)
32
months
21
months

16. Simple Summaries of Significant Studies
CheckMate -816 Study of Nivolumab Plus Chemotherapy Before Surgery for NSCLC1
Full abbreviations, accreditation, and disclosure information available at PeerView.com/GWF40
1. Provided courtesy of Patrick M. Forde, MD.
What were the adverse events?
What do these findings mean?
A serious adverse event is one that is life threatening, requires going to
the hospital, or results in death
In CheckMate -816, people who took nivo plus chemo instead of
chemo alone before their surgery:
Lived longer without
the cancer getting worse
or spreading
Were more likely to have
lungs and lymph nodes
clear of cancer cells
after surgery
Had a trend to live longer
in general, which needs
more time to be confirmed
Did not have more
adverse events
About 1 in 10 people
in each group had a
serious adverse event
from treatment
Most adverse events from surgery were mild or moderate
Most adverse events
from treatment
were mild or
moderate
No people in the nivo plus chemo group died because of serious adverse events or serious surgery-related adverse events due to the treatment
Watch a brief video summary of the CheckMate -816 study: www.nejm.org/do/10.1056/NEJMdo006524/full
Chemo
Nivo plus
chemo
1-2 in 10
1 in 10
Few people had severe or life-threatening adverse events from surgery
Nivo plus chemo is now an
approved treatment in the
United States for adults
with NSCLC whose tumors
are 4 centimeters or larger
or have spread to nearby
lymph nodes